Physician profile
Ronald C Moomaw
NPI 1760504823
$5,994.83
in general payments reported to CMS, 2019-2025
30 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 92% of Occupational Medicine providers received nationally (typical 2025 total: $53.66).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $955 · 2022: $930 · 2023: $1,492 · 2024: $1,200 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,110.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $950.19 | 2021-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $853.15 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $674.78 | 2021-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $385.65 | 2022-2024 | Quviviq |
| Corium, LLC | $355.58 | 2021-2025 | Azstarys |
| Alkermes, INC. | $322.94 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $310.18 | 2023-2025 | Sunosi, Auvelity |
| Janssen Pharmaceuticals, INC | $288.48 | 2023-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $256.72 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $243.60 | 2021-2025 | Trintellix |
| Lundbeck LLC | $210.79 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $186.76 | 2023-2024 | Austedo Xr |
| Neos Therapeutics, Lp | $157.03 | 2021-2025 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $115.40 | 2023-2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $110.18 | 2025 | Cobenfy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $85.35 | 2023-2024 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $80.92 | 2021 | |
| Merck Sharp & Dohme LLC | $73.16 | 2021-2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $58.54 | 2021 | |
| Almatica Pharma LLC | $47.78 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Amgen INC. | $47.01 | 2021 | |
| Bausch Health US, LLC | $28.78 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $24.60 | 2022 | |
| Owp Pharmaceuticals, INC. | $23.09 | 2023 | Subvenite, Lamotrigine |
| Novo Nordisk INC | $22.89 | 2024 | |
| Neurocrine Biosciences, INC. | $22.42 | 2023 | Ingrezza |
| Eisai INC. | $19.50 | 2021 | |
| Glaxosmithkline, LLC. | $13.61 | 2021 | |
| Currax Pharmaceuticals LLC | $13.45 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Moomaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.